Avanafil - CAS 330784-47-9
Catalog number: 330784-47-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Phosphodiesterase (PDE)
A phosphodiesterase (PDE5) inhibitor, used to treat erectile dysfunction.
TA-1790; TA 1790; TA1790; Avanafil; trade name: Stendra; Spedra
Canonical SMILES:
1.A novel liquid chromatographic method with fluorescence detection for quantitation of tadalafil and dapoxetine hydrochloride in pharmaceutical dosage form and human plasma.
Maha H, Amira K, Mohamed A, Ahmed Emad el G. Se Pu. 2015 Jul;33(7):765-70.
Tadalafil (TAD) and dapoxetine HCl (DAP) are recently co-formulated and both show native fluorescence. Therefore, a novel, accurate, specific and sensitive reversed-phase high performance liquid chromatographic method with fluorescence detection was developed and validated for their separation and quantitation in dosage form and human plasma using avanafil as an internal standard (IS). Separation was achieved using isocratic elution within 7.0 min on C18 column and acetonitrile-0.15% triethylamine (40:60, v/v; pH 4) as a mobile phase. The flow rate was 1.0 mL/min and the detection was time-programmed at 330, 410 and 370 nm for TAD, DAP and IS, respectively, after excitation at 236 nm. The linear ranges from 0.01 to 30.00 μg/mL for each drug with the limits of detection of 4.20 and 7.20 ng/mL for TAD and DAP, respectively. The method was validated in accordance to the International Conference on Harmonization (ICH) guidelines and was successfully applied to spiked human plasma with mean recoveries of 98.
2.The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E1,2, Capogrosso P1,2, Montorsi F1,2, Salonia A1,2. Expert Opin Drug Saf. 2016 Feb;15(2):141-52. doi: 10.1517/14740338.2016.1131818. Epub 2016 Jan 9.
INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related adverse events.
3.A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.
Evans JD1, Hill SR1. Patient Prefer Adherence. 2015 Aug 12;9:1159-64. doi: 10.2147/PPA.S56002. eCollection 2015.
BACKGROUND: Numerous pathways can lead to erectile dysfunction (ED) in patients, with some patients having multiple causes. Regardless of the etiology, ED has been successfully treated in many patients with the advent of oral phosphodiesterase-5 inhibitors (PDE5Is). With the release of avanafil, there are currently four PDE5I options available, and choosing between them should be based on patient-specific considerations and preferences.
4.Current use of phosphodiesterase inhibitors in urology.
Hakky TS, Jain L. Turk J Urol. 2015 Jun;41(2):88-92. doi: 10.5152/tud.2015.46354.
The causes of male erectile dysfunction (ED) are quite variable and are now commonly divided into etiologies such as ischemia, smooth muscle damage, or altered blood flow. Although varying rates of ED have been reported in literature, the number of men with ED is projected to increase worldwide by 2025 to approximately 322 million. Since the introduction of phosphodiesterase 5 (PDE5) inhibitors, there has been a paradigm shift in the treatment of ED because PDE5 inhibitors address a broad spectrum of etiologies for ED. Today, the American Urological Association recommends the use of three PDE5 inhibitors (sildenafil, tadalafil, and vardenafil) as a first-line therapy for the treatment of ED. This review evaluates the pharmacological mechanism of PDE5 inhibitors along with the impact and use of sildenafil, vardenafil, tadalafil, and avanafil. By increasing intracellular cGMP levels, PDE5 inhibitors have been shown to be effective in the treatment of ED.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products

CK 3197
(CAS: 132523-92-3)

CK 3197 is a Phosphoric diester hydrolase inhibitor originated by Bayer HealthCare Pharmaceuticals. CK 3197 has hemodynamic and myocardial energetic effects. In...

CAS 60719-84-8 Amrinone

(CAS: 60719-84-8)

Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic ag...

CAS 947620-48-6 RVT-501

(CAS: 947620-48-6)

RVT-501, also referred to E6005, is a selective phosphodiesterase 4 (PDE4) inhibitor (IC50= 2.8 nM) with potential effect to treat atopic dermatitis.

CAS 1238697-26-1 TAK-063

(CAS: 1238697-26-1)

TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for t...

(CAS: 245329-99-1)

CI-1018 is a selective type 4 phosphodiesterase inhibitor associated with vasculitis. CI-1018 has been in development to suppress inflammation.

CAS 959705-64-7 TC-E 5005

TC-E 5005
(CAS: 959705-64-7)

TC-E 5005 is a potent and selective PDE10A inhibitor (IC50 = 7.28, 239, 779, 919, 3100 and 3700 nM at PDE10A, 2A, 11A, 5A, 7B and 3A respectively, and >5000 nM ...

CAS 1013750-77-0 ML-030

(CAS: 1013750-77-0)

ML-030, a triazolothiadiazine, is a potent PDE4 inhibitor in a cell-based cyclic nucleotide-gated cation channel biosensor assay (EC50 = 18.7 nM), with IC50 of ...

CAS 139145-27-0 Parogrelil

(CAS: 139145-27-0)

Parogrelil is a selective and potent PDE III (PDE3) inhibitor with bronchodilating and anti-inflammatory activities.

Chemical Structure

CAS 330784-47-9 Avanafil

Quick Inquiry

Verification code

Featured Items